Clinical trial
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
NCT02937675 is registered in ClinicalTrials.gov with Effector Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
- Lead sponsor
- Effector Therapeutics
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- February 8, 2017
- Completion date
- April 4, 2019
- Enrollment
- 28 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.